CagriSema vs LL-37 (Cathelicidin)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | LL-37 (Cathelicidin) |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to LL-37 (Cathelicidin):
Detailed Analysis
Commonalities
CagriSema and LL-37 (Cathelicidin) are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose LL-37 (Cathelicidin) for Recovery & Healing.
Ready to Learn More?
Looking for trusted sources?